Zymeworks Inc (ZYME) Stock Forecast & Price Target

Zymeworks is supported by a meaningful de-risking of zanidatamab after FDA approval in 1L HER2-positive GEA, where Jazz now sees a $3–5B peak opportunity and Zymeworks is eligible for tiered royalties in the low-to-mid-teens, stepping up to 20% above $2B in annual net sales. The company also received a $250M milestone from Jazz, while its pro-forma cash position of $572.5MM and ongoing share buyback provide balance-sheet strength to fund development and value creation. Beyond zanidatamab, ZW191 and ZW251 are advancing, the pan-RAS inhibitor ADC platform is drawing external interest, and the Theravance acquisition adds potential cash flow streams and a $100MM milestone in 1Q27.

Zymeworks is viewed negatively because its value is heavily dependent on a binary clinical and commercial outcome for zanidatamab, yet the bear case assumes an underwhelming launch and only a 10% probability of success for global royalties and milestones in BTC and GEA. The pipeline is exposed to major clinical, competitive, and regulatory risk, with many drug candidates failing before market approval, while limited differentiation or slower FDA review could sharply reduce future sales and approval odds. Capital intensity and possible dilution add further pressure, as the company must fund development of assets such as ZW191 and ZW251 despite meaningful uncertainty around efficacy, safety, and market uptake.